

Juha Punnonen, et al.  
Application No: 10/828,559  
Page 3

Attorney Docket No. 0344.210US

RECEIVED  
CENTRAL FAX CENTER

JUL 11 2007

AMENDMENTS TO THE CLAIMS:

This listing of claims replaces all prior versions and listings of claims in the application:

1-138. (Canceled)

1 ~~139~~. (Currently Amended) An isolated or recombinant polypeptide comprising a polypeptide sequence that has at least ~~97%~~ 96% sequence identity to a polypeptide sequence comprising amino acid residues 81-265 of SEQ ID NO:4, wherein said isolated or recombinant polypeptide has an ability to induce an immune response against human epithelial cell adhesion molecule (EpCAM) or an antigenic fragment of human EpCAM.

2 ~~140~~. (Currently Amended) An isolated or recombinant ~~The polypeptide of claim 139,~~ ~~wherein the polypeptide comprises~~ comprising a polypeptide sequence that has at least ~~about~~ 97% 96% sequence identity to a polypeptide sequence comprising amino acid residues 24-265 of SEQ ID NO:4, wherein said polypeptide has an ability to induce an immune response against human epithelial cell adhesion molecule (EpCAM) or an antigenic fragment of human EpCAM.

3 ~~141~~. (Currently Amended) An isolated or recombinant ~~The polypeptide of claim 139,~~ ~~wherein the polypeptide comprises~~ comprising a polypeptide sequence that has at least ~~about~~ 96% sequence identity to the polypeptide sequence of SEQ ID NO:4, wherein said polypeptide has an ability to induce an immune response against human epithelial cell adhesion molecule (EpCAM) or an antigenic fragment of human EpCAM.

4 ~~142~~. (Currently Amended) The polypeptide of claim ~~139~~, wherein the polypeptide comprises a polypeptide sequence comprising amino acid residues 81-265 of SEQ ID NO:4.

5 ~~143~~. (Currently Amended) The polypeptide of claim ~~140~~, wherein the polypeptide comprises a polypeptide sequence comprising amino acid residues 24-265 of SEQ ID NO:4.

Juha Punnonen, et al.  
Application No: 10/828,559  
Page 4

Attorney Docket No. 0344.210US

<sup>6</sup>144. (Previously Presented) The polypeptide of claim <sup>3</sup>141, wherein the polypeptide comprises the polypeptide sequence of SEQ ID NO:4.

<sup>7</sup>145. (Previously Presented) The polypeptide of claim <sup>1</sup>139, wherein the polypeptide has an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof.

<sup>8</sup>146. (Previously Presented) The polypeptide of claim <sup>1</sup>139, wherein the polypeptide induces a T cell response against human EpCAM.

<sup>9</sup>147. (Previously Presented) The polypeptide of claim <sup>6</sup>146, wherein the polypeptide T cell proliferation response against human EpCAM.

<sup>10</sup>148. (Previously Presented) The polypeptide of claim <sup>1</sup>139, wherein the polypeptide induces production of at least one cytokine.

<sup>11</sup>149. (Previously Presented) The polypeptide of claim <sup>1</sup>139, wherein the at least one cytokine is interferon-gamma.

<sup>12</sup>150. (Previously Presented) The polypeptide of claim <sup>1</sup>139, wherein the polypeptide is glycosylated and/or pegylated.

<sup>13</sup>151. (Previously Presented) The polypeptide of claim <sup>1</sup>139, wherein the immune response comprises the production of antibodies that bind human EpCAM, proliferation of T cells, and production of one or more cytokines.

<sup>14</sup>152. (Previously Presented) The polypeptide of claim <sup>2</sup>140, wherein the polypeptide has an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof.

Juha Punnonen, et al.  
Application No: 10/828,559  
Page 5

Attorney Docket No. 0344.210US

<sup>15</sup>  
~~153~~. (Previously Presented) The polypeptide of claim ~~140~~<sup>2</sup>, wherein the polypeptide induces a T cell response against human EpCAM.

<sup>16</sup>  
~~154~~. (Previously Presented) The polypeptide of claim ~~140~~<sup>2</sup>, wherein the polypeptide induces production of at least one cytokine.

<sup>17</sup>  
~~155~~. (Previously Presented) The polypeptide of claim ~~140~~<sup>2</sup>, wherein the immune response comprises the production of antibodies that bind human EpCAM, proliferation of T cells, and production of one or more cytokines.

<sup>18</sup>  
~~156~~. (Previously Presented) The polypeptide of claim ~~141~~<sup>3</sup>, wherein the immune response comprises at least one of an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof, induce a T cell response against human EpCAM, or induce production of at least one cytokine.

<sup>19</sup>  
~~157~~. (Previously Presented) A composition comprising the polypeptide of claim ~~139~~<sup>1</sup> and a carrier, diluent, or excipient.

<sup>20</sup>  
~~158~~. (Previously Presented) The composition of claim ~~157~~<sup>19</sup>, wherein the composition further comprises at least one adjuvant, immunomodulatory polypeptide, or cytokine, or any combination thereof.

<sup>21</sup>  
~~159~~. (New) The polypeptide of claim ~~139~~<sup>1</sup>, wherein the polypeptide comprises a polypeptide sequence that has at least 98% sequence identity to a polypeptide sequence comprising amino acid residues 81-265 of SEQ ID NO:4.

<sup>22</sup>  
~~160~~. (New) The polypeptide of claim ~~140~~<sup>2</sup>, wherein the polypeptide comprises a polypeptide sequence that has at least 98% sequence identity to a polypeptide sequence comprising amino acid residues 24-265 of SEQ ID NO:4.

Juha Punnonen, et al.  
Application No: 10/828,559  
Page 6

Attorney Docket No. 0344.210US

<sup>23</sup>  
~~161~~. (New) The polypeptide of claim ~~141~~<sup>3</sup>, wherein the polypeptide comprises a polypeptide sequence that has at least 97% sequence identity to the polypeptide sequence of SEQ ID NO:4.

<sup>24</sup>  
~~162~~. (New) The polypeptide of claim ~~161~~<sup>23</sup>, wherein the polypeptide comprises a polypeptide sequence that has at least 98% sequence identity to the polypeptide sequence of SEQ ID NO:4.

<sup>25</sup>  
~~163~~. (New) A method of inducing an immune response against human EpCAM or an antigenic fragment thereof in a subject, comprising administering to the subject an effective amount of the polypeptide of claim ~~139~~<sup>1</sup>.

<sup>26</sup>  
~~164~~. (New) A method of inducing an immune response against human EpCAM or an antigenic fragment thereof in a subject, comprising administering to the subject an effective amount of the polypeptide of claim ~~140~~<sup>2</sup>.

<sup>27</sup>  
~~165~~. (New) A method of inducing an immune response against human EpCAM or an antigenic fragment thereof in a subject, comprising administering to the subject an effective amount of the polypeptide of claim ~~141~~<sup>3</sup>.

166. (New) A nucleic acid that encodes the polypeptide of claim 139.

167. (New) A nucleic acid that encodes the polypeptide of claim 140.

168. (New) A nucleic acid that encodes the polypeptide of claim 141.